Wolverine Trading’s Avita Medical RCEL Stock Holding History

Wolverine Trading’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-12,051	Closed	-$73K	–	5032
2020 Q2	$73K	Buy	+12,051	New	+$369K	﹤0.01%	4229

Other funds holding RCEL

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Blackcrane Capital Bellevue, Washington $16.3M AUM 19.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

MCF Advisors Covington, Kentucky $2.28B AUM 14.87% 1-Year Est. Return

Wolverine Trading's RCEL Position: Q3 2020 in Review

Wolverine Trading sold out of Avita Medical (RCEL) in Q3 2020, closing a stake of 12,051 shares — an estimated $73K sold.

Wolverine Trading first reported a position in RCEL in Q2 2020 and held it in 1 quarter. The position peaked at $73K in Q2 2020. 43 funds tracked by Wall St. Rank hold RCEL as of Q3 2020.

Wolverine Trading reported no remaining Avita Medical position as of Q3 2020 after selling out during the quarter.
Wolverine Trading sold 12,051 Avita Medical shares in Q3 2020, an estimated $73K.
Wolverine Trading first reported a position in Avita Medical in Q2 2020 and held it in 1 quarter.
Wolverine Trading's Avita Medical position peaked at $73K in Q2 2020.
43 funds tracked by Wall St. Rank held Avita Medical as of Q3 2020.

Based on Wolverine Trading's 13F filing for Q3 2020, filed 13 Nov 2020.